Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jun;39(11):1276-85.
doi: 10.1111/apt.12758. Epub 2014 Apr 16.

Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis

A Alisi  1 , G Bedogni, G Baviera, V Giorgio, E Porro, C Paris, P Giammaria, L Reali, F Anania, V Nobili
Affiliations
Randomized Controlled Trial

Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis

A Alisi et al. Aliment Pharmacol Ther. 2014 Jun.

Abstract

Background: Gut microbiota modifiers may have beneficial effects of non-alcoholic fatty liver disease (NAFLD) but randomised controlled trials (RCT) are lacking in children.

Aim: To perform a double-blind RCT of VSL#3 vs. placebo in obese children with biopsy-proven NAFLD.

Methods: Of 48 randomised children, 44 (22 VSL#3 and 22 placebo) completed the study. The main outcome was the change in fatty liver severity at 4 months as detected by ultrasonography. Secondary outcomes were the changes in triglycerides, insulin resistance as detected by the homoeostasis model assessment (HOMA), alanine transaminase (ALT), body mass index (BMI), glucagon-like peptide 1 (GLP-1) and activated GLP-1 (aGLP-1). Ordinal and linear models with cluster confidence intervals were used to evaluate the efficacy of VSL#3 vs. placebo at 4 months.

Results: At baseline, moderate and severe NAFLD were present in 64% and 36% of PLA children and in 55% and 45% of VSL#3 children. The probability that children supplemented with VSL#3 had none, light, moderate or severe FL at the end of the study was 21%, 70%, 9% and 0% respectively with corresponding values of 0%, 7%, 76% and 17% for the placebo group (P < 0.001). No between-group differences were detected in triglycerides, HOMA and ALT while BMI decreased and GLP-1 and aGLP1 increased in the VSL#3 group (P < 0.001 for all comparisons).

Conclusions: A 4-month supplement of VSL#3 significantly improves NAFLD in children. The VSL#3-dependent GLP-1 increase could be responsible for these beneficial effects. Trial identifier: NCT01650025 (www.clinicaltrial.gov).

PubMed Disclaimer

Conflict of interest statement

Declaration of personal interests: None.

Declaration of funding interests: This study was funded by the Italian Ministry of Health (Fondi di Ricerca Corrente and 5*1000) to Prof. Valerio Nobili. Prof. Anania is supported by US Public Health Service Grant DK062092 and Departments of Veterans’ Affairs Grant BX001746.

Figures

Figure 1
Figure 1
Changes in the severity of fatty liver in the placebo and VSL#3 groups during the study. Values are mean probabilities and standard errors estimated from an ordinal logistic regression model for repeated measures (cluster confidence intervals). For this reason, probabilities at each time point sum to 100. Abbreviations: FL = fatty liver; 0= no fatty liver; 1 = light fatty liver; 2 = moderate fatty liver; 3 = severe fatty liver.
Figure 2
Figure 2
Individual changes of GLP-1 and aGLP-1 in the placebo and VSL#3 groups during the study.
See this image and copyright information in PMC

Comment in

References

    1. King B, Jiang Y, Su X, et al. Weight control, endocrine hormones and cancer prevention. Exp Biol Med (Maywood) 2013;238:502–8. - PubMed
    1. Vazzana N, Santilli F, Sestili S, Cuccurullo C, Davi G. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr Med Chem. 2011;18:5267–80. - PubMed
    1. Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol. 2013;58:1218–29. - PubMed
    1. Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol. 2012;9:152–61. - PubMed
    1. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med. 2012;44:29–40. - PubMed

Publication types

MeSH terms

Substances

Associated data